ATE402254T1 - Aav5 vektoren und deren verwendung - Google Patents

Aav5 vektoren und deren verwendung

Info

Publication number
ATE402254T1
ATE402254T1 AT99926036T AT99926036T ATE402254T1 AT E402254 T1 ATE402254 T1 AT E402254T1 AT 99926036 T AT99926036 T AT 99926036T AT 99926036 T AT99926036 T AT 99926036T AT E402254 T1 ATE402254 T1 AT E402254T1
Authority
AT
Austria
Prior art keywords
aav5
vectors
aav5 vectors
present
particles
Prior art date
Application number
AT99926036T
Other languages
English (en)
Inventor
John Chiorini
Robert Kotin
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE402254T1 publication Critical patent/ATE402254T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
AT99926036T 1998-05-28 1999-05-28 Aav5 vektoren und deren verwendung ATE402254T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8702998P 1998-05-28 1998-05-28

Publications (1)

Publication Number Publication Date
ATE402254T1 true ATE402254T1 (de) 2008-08-15

Family

ID=22202669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926036T ATE402254T1 (de) 1998-05-28 1999-05-28 Aav5 vektoren und deren verwendung

Country Status (9)

Country Link
US (1) US7479554B2 (de)
EP (1) EP1082413B1 (de)
JP (2) JP4060531B2 (de)
AT (1) ATE402254T1 (de)
AU (1) AU762220B2 (de)
CA (2) CA2745131C (de)
DE (1) DE69939169D1 (de)
ES (1) ES2313784T3 (de)
WO (1) WO1999061601A2 (de)

Families Citing this family (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215422A1 (en) 1996-09-11 2003-11-20 John A. Chiorini Aav4 vector and uses thereof
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
WO2001025253A2 (en) 1999-10-01 2001-04-12 The University Of North Carolina At Chapel Hill Temperature-sensitive regulation of viral vector production
US6855314B1 (en) * 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
AU2001250922A1 (en) * 2000-03-22 2001-10-03 Board Of Trustees Of The University Of Arkansas Secreting products from skin by adeno-associated virus (aav) gene transfer
EP1285078A2 (de) 2000-04-28 2003-02-26 The Trustees of The University of Pennsylvania Rekombinante aav vektoren mit aav5 kapsiden und aav5 vektoren pseudotypisiert in heterologen kapsiden
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
DE10120265A1 (de) * 2001-04-25 2002-11-14 Deutsches Krebsforsch AAV-Helferplasmide zur Helfervirus-freien Verpackung und Pseudotypisierung von AAV-Vektoren
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
EP1453547B1 (de) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-assoziierte virus (aav) serotyp 8 sequenzen, diese enthaltende vektoren und ihre verwendung
DK1463805T3 (en) 2001-12-17 2015-01-19 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 9, vectors containing these as well as their uses
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US8927269B2 (en) 2003-05-19 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Avian adenoassociated virus and uses thereof
WO2005021768A1 (en) * 2003-09-01 2005-03-10 Academisch Medisch Centrum Aav vectors for in vivo gene therapy of rheumatoid arthritis
NZ545656A (en) 2003-09-01 2009-02-28 Amc Amsterdam AAV vectors for in vivo gene therapy of rheumatoid arthritis
EP2345731B1 (de) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adenoassoziierte Virus-Claden, Sequenzen, diese enthaltende Vektoren und ihre Verwendungen
WO2005056807A2 (en) * 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Bovine adeno-associated viral (baav) vector and uses thereof
ES2616337T3 (es) 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
WO2006029196A1 (en) * 2004-09-08 2006-03-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of H Ealth Transcytosis of adeno-associated viruses
NZ555830A (en) 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
US8999678B2 (en) 2005-04-07 2015-04-07 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
JP2012521750A (ja) 2009-03-27 2012-09-20 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 肝硬変及び肝線維症の治療のための方法及び組成物
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
EP2497830A1 (de) 2009-11-05 2012-09-12 Proyecto de Biomedicina Cima, S.L. Regulierte expressionssysteme
WO2011088081A1 (en) 2010-01-12 2011-07-21 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
JP2013533847A (ja) 2010-04-23 2013-08-29 ユニバーシティ オブ マサチューセッツ コレステロール関連障害のａａｖベースの治療
US9546369B2 (en) 2010-04-23 2017-01-17 University Of Massachusetts Multicistronic expression constructs
ES2605305T3 (es) 2010-04-23 2017-03-13 University Of Massachusetts Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos
ES2711256T3 (es) * 2010-04-23 2019-04-30 Univ Florida Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2012145624A2 (en) 2011-04-21 2012-10-26 University Of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
RU2611202C2 (ru) 2011-04-22 2017-02-21 Те Риджентс Оф Те Юниверсити Оф Калифорния Вирионы аденоассоциированного вируса с вариантным капсидом и способы их использования
BR112014020127A2 (pt) * 2012-02-14 2020-06-30 The Regents Of The University Of Calefornia métodos para tratamento, melhoramento ou proteção (prevenção) de um indivíduo ou um paciente, e de uma disfunção, uma doença, uma infecção ou uma condição, e, método para suprimir o ganho de peso, ou suprimir o apepite, ou estimular ou iniciar a perda de peso
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
DK2900686T3 (da) 2012-09-28 2020-08-17 Univ North Carolina Chapel Hill Aav-vektorer targeteret til oligodendrocytter
US9597357B2 (en) 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014143932A1 (en) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
EP3008191A2 (de) 2013-06-13 2016-04-20 Shire Human Genetic Therapies, Inc. Virenproduktion auf messenger-rna-basis
KR102445330B1 (ko) * 2013-07-12 2022-09-19 더 칠드런스 호스피탈 오브 필라델피아 Ａａｖ 벡터 및 항―ａａｖ （아데노-관련 바이러스） 중화 항체에 대한 검정
WO2015044292A1 (en) 2013-09-26 2015-04-02 Universitat Autonoma De Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
PL3102722T3 (pl) 2014-02-04 2021-03-08 Jumpcode Genomics, Inc. Frakcjonowanie genomu
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
US10072251B2 (en) 2014-02-19 2018-09-11 University Of Massachusetts Recombinant AAVS having useful transcytosis properties
EP3778627A1 (de) 2014-03-09 2021-02-17 The Trustees of The University of Pennsylvania Zusammensetzungen für die behandlung des mangels von ornithin-transcarbamylase (otc)
DK3117005T3 (da) 2014-03-10 2024-08-12 Uniqure Ip Bv Yderligere forbedrede AVV-vektorer, der er produceret i insektceller
EP3119797B1 (de) 2014-03-18 2020-12-23 University of Massachusetts Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
WO2015187825A2 (en) 2014-06-03 2015-12-10 University Of Massachusetts Compositions and methods for modulating dysferlin expression
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
US10711270B2 (en) 2014-10-03 2020-07-14 University Of Massachusetts High efficiency library-identified AAV vectors
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
RU2020140209A (ru) * 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
SG10202001102XA (en) 2014-11-14 2020-03-30 Voyager Therapeutics Inc Modulatory polynucleotides
CN107109407A (zh) 2014-11-14 2017-08-29 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
CN114480440A (zh) 2014-11-21 2022-05-13 北卡罗来纳-查佩尔山大学 靶向中枢神经系统的aav载体
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3978614A3 (de) 2015-01-07 2022-07-27 Universitat Autònoma de Barcelona Einzelvektor-genkonstrukt mit insulin und glucokinasegenen
EP3245220B1 (de) 2015-01-14 2023-09-20 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen für gezielten gentransfer
CN107531774B (zh) 2015-02-06 2021-12-14 北卡罗来纳大学查珀尔希尔分校 优化的人类凝血因子viii基因表达盒及其用途
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
US10968536B2 (en) 2015-02-25 2021-04-06 Jumpcode Genomics, Inc. Methods and compositions for sequencing
US10081659B2 (en) 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
CA3021949C (en) 2015-04-24 2023-10-17 University Of Massachusetts Modified aav constructs and uses thereof
US20190000943A1 (en) * 2015-08-13 2019-01-03 Aavet Therapeutics, Llc Aav6 vectors for immunotherapy
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
EP3355924A1 (de) 2015-09-29 2018-08-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Verfahren zur behandlung und prävention von amyotropher lateralsklerose
US11253576B2 (en) 2015-10-22 2022-02-22 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
CA3002980A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
BR112018007453A2 (pt) 2015-11-05 2018-10-23 Bamboo Therapeutics Inc genes modificados de ataxia de friedreich e vetores para a terapia gênica
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
EP3390429B1 (de) 2015-12-14 2025-06-18 The University of North Carolina at Chapel Hill Modifizierte kapsidproteine zur verbesserten abgabe von parvovirus-vektoren
WO2017129822A1 (en) * 2016-01-29 2017-08-03 Sirion Biotech Gmbh Aav-based conditional expression system
US11826433B2 (en) 2016-02-02 2023-11-28 University Of Massachusetts Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
FI3411484T3 (fi) 2016-02-05 2023-11-15 Univ Emory Yksisäikeisen tai itsekomplementaarisen adenoassosioidun viruksen 9 injektio serebrospinaaliseen fluidiin
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11339427B2 (en) 2016-02-12 2022-05-24 Jumpcode Genomics, Inc. Method for target specific RNA transcription of DNA sequences
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
BR112018017125A2 (pt) 2016-02-22 2018-12-26 The University Of North Carolina At Chapel Hill vetor aav-idua para tratamento de cegueira associada a mps i
IL261642B2 (en) 2016-03-07 2026-01-01 Univ Iowa Res Found AAV-mediated expression using a synthetic promoter and enhancer
US11207426B2 (en) 2016-04-05 2021-12-28 University Of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
US10585103B2 (en) 2016-04-28 2020-03-10 The Trustees Of Indiana University Methods and compositions for resolving components of a virus preparation
EP4049683A1 (de) 2016-04-29 2022-08-31 Adverum Biotechnologies, Inc. Evasion von neutralisierenden antikörpern durch ein rekombinantes adeno-assoziiertes virus
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
EP3448987A4 (de) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
CR20180589A (es) 2016-05-13 2019-02-27 4D Molecular Therapeutics Inc Cápsulas variantes de virus adenoasociados y métodos de uso de estas
EP3458589A4 (de) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus huntington
EP3458588B1 (de) 2016-05-18 2025-10-29 Voyager Therapeutics, Inc. Modulatorische polynukleotide
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
JP2019517274A (ja) 2016-06-13 2019-06-24 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 最適化されたｃｌｎ１遺伝子および発現カセットおよびそれらの使用
US11882815B2 (en) 2016-06-15 2024-01-30 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
WO2017221145A1 (en) 2016-06-21 2017-12-28 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
BR112019001344A2 (pt) 2016-07-26 2019-04-30 The University Of North Carolina At Chapel Hill tolerância imunológica mediada por vetor no olho
CA3035522A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
CN110506119A (zh) 2016-10-13 2019-11-26 马萨诸塞大学 Aav衣壳设计
EP3528785A4 (de) 2016-10-19 2020-12-02 Adverum Biotechnologies, Inc. Modifizierte aav-kaspide und verwendungen davon
EP3535396A1 (de) 2016-11-01 2019-09-11 Novartis AG Verfahren und zusammensetzungen zur verbesserung der genbearbeitung
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
WO2018134168A1 (en) 2017-01-17 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors
JP7081767B2 (ja) * 2017-01-30 2022-06-07 学校法人日本医科大学 アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体
CN110770346B (zh) 2017-03-15 2024-01-12 北卡罗来纳-查佩尔山大学 多倍体腺相关病毒载体及其制备和使用方法
EP3388520A1 (de) 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzung zur reduzierung der expression von nkcc1 in einer darauf angewiesenen person
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
AU2018261790B2 (en) 2017-05-05 2024-10-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2018208972A1 (en) 2017-05-09 2018-11-15 University Of Massachusetts Methods of treating amyotrophic lateral sclerosis (als)
KR102765034B1 (ko) 2017-05-24 2025-02-11 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3106446A1 (en) 2017-07-13 2019-01-17 University Of Miami Method for managing pain
EP3654860A1 (de) 2017-07-17 2020-05-27 Voyager Therapeutics, Inc. Trajektoriearrayführungssystem
EP3658577A1 (de) 2017-07-27 2020-06-03 Novartis AG Sheddase-resistente trem2-varianten
CN111448308A (zh) 2017-08-03 2020-07-24 沃雅戈治疗公司 递送aav的组合物和方法
WO2019040586A1 (en) * 2017-08-25 2019-02-28 Ovid Therapeutics Inc. RECOMBINANT ADENO-ASSOCIATE VECTORS
EP4218828A3 (de) 2017-09-20 2023-09-27 4D Molecular Therapeutics Inc. Kapside mit adeno-assoziierten virenvarianten und verfahren zur verwendung davon
WO2019060538A1 (en) 2017-09-20 2019-03-28 The Trustees Of Indiana University METHODS FOR LIPOPROTEIN RESOLUTION BY MASS SPECTROMETRY
CA3075643A1 (en) 2017-09-22 2019-03-28 University Of Massachusetts Sod1 dual expression vectors and uses thereof
US20200263199A1 (en) 2017-09-29 2020-08-20 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP3697908A1 (de) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
EP3697448A1 (de) 2017-10-20 2020-08-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur expression eines bestimmten polynukleotids in den zapfen-fotorezeptoren einer person mit subretinaler abgabe einer therapeutisch wirksamen menge eines rekombinanten aav9-vektors
BR112020008835A2 (pt) 2017-11-07 2020-10-20 The University Of North Carolina At Chapel Hill genes de aga otimizados e cassetes de expressão e seu uso
KR102793696B1 (ko) 2017-11-27 2025-04-09 4디 몰레큘러 테라퓨틱스 아이엔씨. 아데노-관련 바이러스 변이체 캡시드 및 혈관 신생을 억제하기 위한 용도
US11232941B2 (en) 2018-01-12 2022-01-25 The Trustees Of Indiana University Electrostatic linear ion trap design for charge detection mass spectrometry
CN111601620A (zh) * 2018-01-17 2020-08-28 阿瑞纳斯治疗公司 用于21-羟化酶缺乏症的腺相关病毒基因疗法
EP3746153A4 (de) 2018-02-21 2021-11-10 Alcyone Lifesciences, Inc. Systeme und verfahren zur abgabe von flüssigkeiten
BR112020016699A2 (pt) 2018-02-28 2020-12-15 The University Of North Carolina At Chapel Hill Métodos e composições para vetores de vírus de evasão de anticorpos
SG11202009450SA (en) 2018-04-03 2020-10-29 Stridebio Inc Virus vectors for targeting ophthalmic tissues
CN112272672A (zh) 2018-04-03 2021-01-26 斯特里迪比奥公司 抗体逃避性病毒载体
SG11202009451VA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
JP7611702B2 (ja) 2018-05-06 2025-01-10 エメンドバイオ インコーポレーテッド ヘテロ接合性ｅｌａｎｅ遺伝子の対立遺伝子の差次的ノックアウト
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
AU2019281255B2 (en) 2018-06-04 2023-01-12 The Trustees Of Indiana University Ion trap array for high throughput charge detection mass spectrometry
WO2019236143A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
JP7398810B2 (ja) 2018-06-04 2023-12-15 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 静電線形イオン・トラップにイオンを捕獲する装置および方法
US11315780B2 (en) 2018-06-04 2022-04-26 The Trustees Of Indiana University Charge detection mass spectrometry with real time analysis and signal optimization
WO2019236139A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
US12163129B2 (en) 2018-06-08 2024-12-10 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
CN119242659A (zh) 2018-06-12 2025-01-03 北卡罗来纳大学教堂山分校 合成嗜肝性腺相关病毒衣壳及其用途
US12060567B2 (en) 2018-06-13 2024-08-13 Voyager Therapeutics, Inc. Engineered untranslated regions (UTR) for AAV production
FI3814513T3 (fi) 2018-06-28 2025-05-28 Univ North Carolina Chapel Hill Optimoidut cln5-geenit ja -ilmentymiskasetit sekä niiden käyttö
CA3107462A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
IL280300B2 (en) 2018-08-10 2025-06-01 Univ North Carolina Chapel Hill Optimized cln7 genes and expression cassettes and their use
AU2019327386A1 (en) 2018-08-27 2021-03-18 Alcyone Therapeutics, Inc. Fluid delivery systems and methods
WO2020069029A1 (en) 2018-09-26 2020-04-02 Emendobio Inc. Novel crispr nucleases
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
WO2020072844A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
JP2022505106A (ja) 2018-10-15 2022-01-14 ボイジャー セラピューティクス インコーポレイテッド バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
BR112021006074A2 (pt) 2018-11-05 2021-07-20 The University Of North Carolina At Chapel Hill genes e cassetes de expressão fig4 otimizados e seu uso
EP3884510A1 (de) 2018-11-20 2021-09-29 The Trustees of Indiana University Orbitrap für einzelteilchen-massenspektrometrie
AU2019392058B2 (en) 2018-12-03 2024-12-05 The Trustees Of Indiana University Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
WO2020132385A1 (en) 2018-12-21 2020-06-25 The University Of North Carolina At Chapel Hill Optimized galc genes and expression cassettes and their use
WO2020163379A1 (en) 2019-02-05 2020-08-13 Emendobio Inc. Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
WO2020163307A1 (en) 2019-02-06 2020-08-13 Emendobio Inc. New engineered high fidelity cas9
WO2020174369A2 (en) 2019-02-25 2020-09-03 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
CN113677801A (zh) 2019-02-25 2021-11-19 诺华股份有限公司 治疗bietti晶体营养不良的组合物和方法
SG11202110146VA (en) 2019-03-21 2021-10-28 Stridebio Inc Recombinant adeno-associated virus vectors
JP7630176B2 (ja) 2019-04-01 2025-02-17 テナヤ セラピューティクス， インコーポレイテッド 操作されたカプシドを有するアデノ随伴ウイルス
CA3136872A1 (en) 2019-04-23 2020-10-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) New adeno-associated virus (aav) variants and uses thereof for gene therapy
WO2020219527A1 (en) 2019-04-23 2020-10-29 The Trustees Of Indiana University Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
US11981967B2 (en) 2019-04-26 2024-05-14 Sangamo Therapeutics, Inc. Engineering AAV
CA3144654A1 (en) 2019-04-29 2020-11-05 The University Of North Carolina At Chapel Hill Optimized sumf1 genes and expression cassettes and their use
TW202104592A (zh) * 2019-05-14 2021-02-01 美商拜奧馬林製藥公司 重複投予基因療法載體之方法
WO2020237130A1 (en) 2019-05-22 2020-11-26 The University Of North Carolina At Chapel Hill Ube3a genes and expression cassettes and their use
CN114989267A (zh) * 2019-05-24 2022-09-02 瑞泽恩制药公司 经修饰的病毒颗粒和其用途
CA3144864A1 (en) 2019-06-27 2020-12-30 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
EP3914720B9 (de) 2019-07-10 2023-09-27 Masonic Medical Research Laboratory Vgll4 mit ucp-1-cis-regulierendem element und verfahren zu dessen verwendung
US10801042B1 (en) 2019-07-15 2020-10-13 Vigene Biosciences, Inc. Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
US10557149B1 (en) 2019-07-15 2020-02-11 Vigene Biosciences, Inc. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
US10653731B1 (en) 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN120109003A (zh) 2019-09-25 2025-06-06 印地安纳大学理事会 用于脉冲模式电荷检测质谱法的设备和方法
GB201913974D0 (en) 2019-09-27 2019-11-13 King S College London Vector
JP7659325B2 (ja) 2019-10-10 2025-04-09 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 粒子を識別、選択、および純化するためのシステムおよび方法
US20230392163A1 (en) 2019-10-17 2023-12-07 Ginkgo Bioworks Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
WO2021126972A1 (en) 2019-12-18 2021-06-24 The Trustees Of Indiana University Mass spectrometer with charge measurement arrangement
JP7607355B2 (ja) 2020-02-03 2024-12-27 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 電荷検出質量分析用信号の時間ドメイン分析
US20230136699A1 (en) 2020-02-28 2023-05-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Gene therapy for maple syrup urine disease
US20230158173A1 (en) 2020-03-20 2023-05-25 University Of Florida Research Foundation, Inc. Gene therapy for cockayne syndrome
EP4100532A4 (de) 2020-03-23 2024-03-27 The University of North Carolina at Chapel Hill Aav-naglu-vektoren zur behandlung von mukopolysaccharidose iiib
EP4132955A2 (de) 2020-04-10 2023-02-15 SOLA Biosciences LLC Zusammensetzungen und verfahren zur behandlung von proteinaggregationsstörungen
DK4100539T3 (da) 2020-04-27 2026-02-16 4D Molecular Therapeutics Inc Adenoassocierede varianter, formuleringer og fremgangsmåder til pulmonal indgivelse
MX2022013288A (es) 2020-04-28 2023-02-22 Sola Biosciences Llc Composiciones y metodos para el tratamiento de proteinopatias por la proteina 43 de union a acido desoxirribonucleico (adn) de respuesta transactiva (tdp-43).
MX2022013819A (es) 2020-05-05 2023-01-30 Univ North Carolina Chapel Hill Capsides de virus adeno-asociado 5 modificado y usos del mismo.
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
EP4161953A1 (de) 2020-06-05 2023-04-12 SOLA Biosciences LLC Zusammensetzungen und verfahren zur behandlung von synukleinopathien
ES3057565T3 (en) 2020-07-23 2026-03-03 Univ North Carolina Chapel Hill Optimized slc13a5 genes and expression cassettes and their use
CN116745409A (zh) 2020-08-19 2023-09-12 萨雷普塔治疗公司 用于治疗雷特综合征的腺相关病毒载体
WO2022076648A1 (en) 2020-10-09 2022-04-14 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
EP4240861A1 (de) 2020-11-03 2023-09-13 Pfizer Inc. Verfahren zur reinigung von aav-vektoren durch anionenaustauschchromatografie
WO2022130172A1 (en) 2020-12-15 2022-06-23 Pfizer Inc. Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
MX2023007612A (es) 2020-12-23 2023-07-12 Pfizer Metodos para purificacion de vectores aav por cromatografia de afinidad.
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
WO2022208342A1 (en) 2021-04-01 2022-10-06 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4329820A1 (de) 2021-04-26 2024-03-06 Alexion Pharma International Operations Limited Adeno-assoziierte virale vektorkapside mit verbessertem gewebetropismus
KR20240014477A (ko) 2021-05-28 2024-02-01 상하이 레제네리드 테라피즈 컴퍼니 리미티드 변이체 캡시드를 갖는 재조합 아데노-연관 바이러스 및 이의 응용
US12570977B2 (en) * 2021-06-12 2026-03-10 Mello Biotech Taiwan Co., Ltd. mRNA composition and production method for use in anti-viral and anti-cancer vaccines
EP4359547A1 (de) 2021-06-22 2024-05-01 Pfizer Inc. Herstellung eines adeno-assoziierten virusvektors in insektenzellen
EP4367251A1 (de) 2021-07-08 2024-05-15 Tenaya Therapeutics, Inc. Optimierte expressionskassetten für die gentherapie
EP4384195A2 (de) 2021-08-11 2024-06-19 King's College London Zusammensetzungen und verfahren zur verbesserten behandlung von erkrankungen mit einfluss auf das zentrale nervensystem
US20250042958A1 (en) 2021-10-08 2025-02-06 Sola Biosciences Llc Compositions and methods for the treatment of proteopathies
JP2024537178A (ja) 2021-10-08 2024-10-10 ソラ・バイオサイエンシズ・エルエルシー ｐ５３媒介性癌の処置のための組成物および方法
AU2022368907A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Rejuvenation treatment of age-related white matter loss
JP2024542015A (ja) 2021-11-02 2024-11-13 ユニバーシティ オブ ロチェスター 脳内でのｔｃｆ７ｌ２媒介性髄鞘再生
JP2024540181A (ja) 2021-11-04 2024-10-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 骨格筋に再標的化されたウイルス粒子
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
WO2023150687A1 (en) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors, and methods of use thereof
EP4508062A1 (de) 2022-04-11 2025-02-19 Tenaya Therapeutics, Inc. Adeno-assoziiertes virus mit manipuliertem kapsid
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
US20250353883A1 (en) 2022-05-06 2025-11-20 Novartis Ag Novel recombinant aav vp2 fusion polypeptides
CN119604610A (zh) 2022-05-09 2025-03-11 瑞泽恩制药公司 用于体内抗体产生的载体和方法
WO2024003687A1 (en) 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
AU2023314923A1 (en) 2022-07-29 2025-02-27 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
WO2024038365A1 (en) 2022-08-16 2024-02-22 Pfizer Inc. Methods for purification of aav vectors by anion exchange chromatography
EP4619438A2 (de) 2022-11-14 2025-09-24 Regeneron Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur fibroblastenwachstumsfaktorrezeptor-3-vermittelten abgabe an astrozyten
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
KR20250134733A (ko) 2022-12-16 2025-09-11 리제너론 파아마슈티컬스, 인크. Aav 입자에 결합하는 항원-결합 분자 및 용도
WO2024147114A1 (en) 2023-01-06 2024-07-11 Bloomsbury Genetic Therapies Limited Compositions and methods for treating parkinson's disease
EP4658294A2 (de) 2023-02-02 2025-12-10 University of Rochester Kompetitiver ersatz von gliazellen
CN120677178A (zh) 2023-02-13 2025-09-19 瑞泽恩制药公司 用抗人cacng1抗体治疗肌肉相关病症
WO2024215653A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
AU2024265507A1 (en) 2023-05-02 2025-10-30 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025042428A1 (en) 2023-08-18 2025-02-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules and uses thereof
WO2025082618A1 (en) 2023-10-20 2025-04-24 Fuse Vectors Aps In vitro parvovirus capsid manufacturing
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
WO2025090858A1 (en) 2023-10-27 2025-05-01 Biogen Ma Inc. Methods for identifying aav capsid variants with desired characteristics
WO2025151796A1 (en) 2024-01-11 2025-07-17 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025250457A1 (en) 2024-05-28 2025-12-04 University Of Rochester Enhanced brain transduction by gene therapeutics
WO2025255452A2 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses thereof
WO2026017965A1 (en) 2024-07-19 2026-01-22 The University Court Of The University Of Edinburgh Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions
WO2026025058A1 (en) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Aav viral particles retargeted to egfr-expressing cancer cells
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
DK0725837T3 (da) * 1993-10-28 2000-06-13 Deutsches Krebsforsch Adeno-associeret virus - dettes diagnostiske anvendelse ved tidlig abort
CA2187626C (en) 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
DE4436664A1 (de) * 1994-10-13 1996-07-04 Max Planck Gesellschaft Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen
US6342390B1 (en) * 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US5843742A (en) 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
WO1997006272A2 (en) 1995-08-03 1997-02-20 Avigen, Inc. High efficiency helper system for aav vector production
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US20030215422A1 (en) * 1996-09-11 2003-11-20 John A. Chiorini Aav4 vector and uses thereof
EP1005376B1 (de) * 1997-03-14 2010-11-03 The Children's Hospital of Philadelphia Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
IT1291135B1 (it) * 1997-04-08 1998-12-29 Angeletti P Ist Richerche Bio Vettori ricombinanti utilizzabili in terapia genica
ATE316576T1 (de) 1998-05-27 2006-02-15 Avigen Inc Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
WO1999061643A1 (en) 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
DE19849643A1 (de) 1998-10-29 2000-05-04 Deutsches Krebsforsch An das AAV-Kapsid bindender, den Zelltropismus verändernder Antikörper und Verfahren zum gerichteten Gentransfer
AU768729B2 (en) 1998-11-05 2004-01-08 Trustees Of The University Of Pennsylvania, The Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO2000066720A2 (en) 1999-04-30 2000-11-09 City Of Hope The use of adeno-associated virus (aav) deliver cytoprotective genes
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US20020076754A1 (en) 2000-04-20 2002-06-20 Liangwu Sun Overcoming AAV vector size limitation through viral DNA hetero-dimerization
EP1285078A2 (de) 2000-04-28 2003-02-26 The Trustees of The University of Pennsylvania Rekombinante aav vektoren mit aav5 kapsiden und aav5 vektoren pseudotypisiert in heterologen kapsiden
US7378272B2 (en) 2001-03-27 2008-05-27 New York University Packaging cell lines for the continuous production of alphavirus vectors
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
EP1453547B1 (de) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-assoziierte virus (aav) serotyp 8 sequenzen, diese enthaltende vektoren und ihre verwendung
US20060127358A1 (en) 2002-05-01 2006-06-15 Nicholas Muzyczka Raav expression systems and methods for enhancing transduction of mammalian neural cells
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US8927269B2 (en) 2003-05-19 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Avian adenoassociated virus and uses thereof
PL3235827T3 (pl) 2003-06-19 2021-07-05 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowania
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes

Also Published As

Publication number Publication date
US20050255089A1 (en) 2005-11-17
EP1082413A2 (de) 2001-03-14
WO1999061601A3 (en) 2000-02-17
AU762220B2 (en) 2003-06-19
CA2329060C (en) 2011-09-13
DE69939169D1 (de) 2008-09-04
AU4220599A (en) 1999-12-13
CA2329060A1 (en) 1999-12-02
JP4060531B2 (ja) 2008-03-12
EP1082413B1 (de) 2008-07-23
ES2313784T3 (es) 2009-03-01
WO1999061601A2 (en) 1999-12-02
JP4191771B2 (ja) 2008-12-03
CA2745131C (en) 2016-08-09
JP2002516092A (ja) 2002-06-04
JP2007209347A (ja) 2007-08-23
US7479554B2 (en) 2009-01-20
CA2745131A1 (en) 1999-12-02
WO1999061601A9 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
DE69939169D1 (de) Aav5 vektoren und deren verwendung
WO1998011244A3 (en) AAV4 vector and uses thereof
DE69936104D1 (de) Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
DE69637147D1 (de) Transportproteine und deren verwendungen
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
WO2005056807A3 (en) Bovine adeno-associated viral (baav) vector and uses thereof
ATE399873T1 (de) Defekte adenovirus-vektoren und deren verwendung in der gentherapie
EP1131333A4 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DE69718327D1 (de) Graphitteilchen und lithiumsekundärzelle in denen dieselben als kathodematerial verwendet werden
ATE318900T1 (de) Ef-1-alpha transkriptionsregulatorische dna aus hamster
DE69637256D1 (de) Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
DE3676148D1 (de) Antigerinnungsmittel, verfahren zu seiner herstellung und dieses mittel als wirkender grundstoff enthaltende antikoagulantia.
NO995182L (no) Pattedyrcytokinlignende faktor 7
DE69927795D1 (en) Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
ATE171212T1 (de) Corticotropin freisetzende rezeptoren des faktor 2
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
EP1845163A3 (de) Adeno-assoziierte Virus-Serotyp-I-Nukleinsäuresequenzen und diese enthaltende Vektoren und Wirtszellen
TR199902434T2 (xx) Bakteriyel plazmidler.
HUP0102413A1 (hu) Vektorok nukleinsavak bevitelére, ezeket tartalmazó készítmények és alkalmazásuk
NO950420D0 (no) Interferon endelse derav
ATE320266T1 (de) Induktion von antigen-spezifischen t-zellen durch interferon
HUP9904201A1 (hu) Génterápiában használható, egy exogén nukleinsavat genomjában beépítve tartalmazó rekombináns vírus és egy nem virális és nem plazmid transzfektáló szer kombinációját tartalmazó transzfektáló készítmény

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties